GlaxoSmithkline Pharmaceuticals Ltd.
GLAXO · ISIN: INE159A01016
GlaxoSmithkline Pharmaceuticals Ltd. is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE159A01016.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.06%), NIFTY LMC 250 TRI (0.14%), NIFTY MC 150 TRI (0.28%)
CHART
GlaxoSmithkline Pharmaceuticals Ltd. - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-9.18%
3M
-5.28%
6M
+7.65%
1Y
-8.81%
3Y CAGR
+20.9%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
GlaxoSmithkline Pharmaceuticals Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
F&O Sentiment
Nearest expiry: 2012-09-27 · As of 2012-09-27.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2018-09-11 | BONUS | 0.500000 | BONUS 1:1 |
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-08-19 | SHORT_SELL | 1 |
| 2026-08-10 | SHORT_SELL | 50 |
Frequently asked questions
What is GlaxoSmithkline Pharmaceuticals Ltd.'s 1-year and 3-year return?
GlaxoSmithkline Pharmaceuticals Ltd.'s 1-year price return is -8.81%. Its 3-year CAGR (annualized return) is +20.9%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is GlaxoSmithkline Pharmaceuticals Ltd.'s latest financial performance?
GlaxoSmithkline Pharmaceuticals Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹3,955 Cr, with a TTM profit after tax of ₹1,068 Cr and an EBITDA margin of 36.73%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹62.01, with a 5-year EPS growth rate of 23.29% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is GlaxoSmithkline Pharmaceuticals Ltd.'s quality score?
GlaxoSmithkline Pharmaceuticals Ltd. has a Punji quality score of 80 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do GlaxoSmithkline Pharmaceuticals Ltd.'s technical indicators show?
As of 2026-10-29, GlaxoSmithkline Pharmaceuticals Ltd.'s RSI (14-day) is 40.6 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of GlaxoSmithkline Pharmaceuticals Ltd.?
As of 2026-06-30, GlaxoSmithkline Pharmaceuticals Ltd.'s shareholding is split across Promoter (75%), Public (25%). Promoter holding of 75% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is GlaxoSmithkline Pharmaceuticals Ltd. part of any major market index?
Yes - GlaxoSmithkline Pharmaceuticals Ltd. is a constituent of NIFTY 500 TRI (0.06% weight) and NIFTY LMC 250 TRI (0.14% weight) and NIFTY MC 150 TRI (0.28% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for GlaxoSmithkline Pharmaceuticals Ltd.?
As of 2012-09-27 (nearest expiry 2012-09-27), GlaxoSmithkline Pharmaceuticals Ltd.'s put-call ratio by open interest is 0 - below 1, typically read as bullish positioning (more open interest on calls than puts). The max pain strike is ₹1350, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
Has GlaxoSmithkline Pharmaceuticals Ltd. seen any recent bulk or block deals?
Yes, as of 2026-08-19 - the most recent recorded deal was a SHORT_SELL on 2026-08-19 for 1 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
What corporate actions has GlaxoSmithkline Pharmaceuticals Ltd. announced recently?
The most recent corporate action for GlaxoSmithkline Pharmaceuticals Ltd. is a BONUS (0.500000) with an ex-date of 2018-09-11, for: BONUS 1:1. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns